Sveriges Riksbank
RESULT OF RIKSBANK AUCTIONS GOVERNMENT BONDS
RESULT OF RIKSBANK AUCTIONS GOVERNMENT BONDS
| Auction date | 2025-10-17 |
| Loan | 1061 |
| Coupon | 0.75 % |
| ISIN-code | SE0011281922 |
| Maturity | 2029-11-12 |
| Tendered volume, SEK mln | 2000 +/- 2000 |
| Total bid volume, SEK mln | 3,975 |
| Volume sold, SEK mln | 1,925 |
| Number of bids | 16 |
| Number of accepted bids | 8 |
| Average yield | 1.918 % |
| Lowest yield | 1.903 % |
| Highest accepted yield | 1.925 % |
| % accepted at highest yield | 100.00 |
| Auction date | 2025-10-17 |
| Loan | 1053 |
| Coupon | 3.50 % |
| ISIN-code | SE0002829192 |
| Maturity | 2039-03-30 |
| Tendered volume, SEK mln | 700 +/- 700 |
| Total bid volume, SEK mln | 3,140 |
| Volume sold, SEK mln | 775 |
| Number of bids | 15 |
| Number of accepted bids | 2 |
| Average yield | 2.627 % |
| Lowest yield | 2.627 % |
| Highest accepted yield | 2.629 % |
| % accepted at highest yield | 10.71 |
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Novartis Pharma AG17.10.2025 12:37:04 CEST | Press release
Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML
iFLYTEK17.10.2025 12:33:00 CEST | Press release
iFLYTEK AINOTE 2 Launches: A Game-Changer for Professional Productivity
F. Hoffmann-La Roche Ltd17.10.2025 12:30:00 CEST | Press release
CHMP recommends EU approval of Roche’s Gazyva/Gazyvaro for lupus nephritis
Harvia Oyj17.10.2025 12:00:32 CEST | Press release
Harvia Plc distributes a dividend of EUR 0.37 per share
Helsinn Healthcare S.A.17.10.2025 11:00:00 CEST | Press release
AKYNZEO® demonstrates superior prevention of chemotherapy-induced nausea and vomiting compared to the standard of care in patients receiving moderately emetogenic chemotherapy with additional predictive factors
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom